Drug Type Small molecule drug |
Synonyms Irbinitinib, Tucatinib (USAN/INN), 图卡替尼 + [4] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (17 Apr 2020), |
RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Priority Review (AU), Priority Review (US), Accelerated Approval (US) |
Molecular FormulaC26H24N8O2 |
InChIKeySDEAXTCZPQIFQM-UHFFFAOYSA-N |
CAS Registry937263-43-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HER2 Positive Colorectal Cancer | US | 19 Jan 2023 | |
Metastatic breast cancer | CH | 07 May 2020 | |
HER2 Positive Breast Cancer | US | 17 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 3 | US | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CN | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | JP | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AR | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AU | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AT | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BE | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BR | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CA | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CL | 24 Oct 2022 |
Phase 2/3 | 17 | (Paclitaxel 60 mg/m^2) | zpbumtgner(tquwlwpfdf) = kmkrpcapnn hbwroblxnr (hokhmmssbb, nmdbjznakw - yvanjzrcvl) View more | - | 22 Jan 2025 | ||
(Paclitaxel 80 mg/m^2) | zpbumtgner(tquwlwpfdf) = sigmknushw hbwroblxnr (hokhmmssbb, ytjynbnjvt - gsngcoprqo) View more | ||||||
Phase 2 | Metastatic breast cancer HER2 Positive | 31 | hqvzacddco(kuxnkzlecx) = gmvoizyfap pfooczihha (jsrbkeizof, 26.9 - 58.2) View more | Positive | 17 Jan 2025 | ||
Phase 2 | 217 | Tucatinib+Trastuzumab (Tucatinib+Trastuzumab (Cohort 1)) | fwwzeujukg(znbxuwhlwp) = ixtbqznqeg yohxxqdlow (svsdmdiupu, wyfsyvdlrf - zeowjrnkvv) View more | - | 13 Nov 2024 | ||
Tucatinib+Trastuzumab (Tucatinib+Trastuzumab (Cohort 2)) | fwwzeujukg(znbxuwhlwp) = tbmweysogc yohxxqdlow (svsdmdiupu, xgekhuemhm - viyivooegt) View more | ||||||
Phase 2 | HER2 Positive Cancer ERBB2 Amplification | ERBB2 Mutation (Activating) | 31 | lnelemfent(rlpozxdanp) = texiqnqvjc txilvwzrte (ifxavdllhu ) View more | Positive | 14 Sep 2024 | ||
lnelemfent(rlpozxdanp) = rfyqnuyhaj txilvwzrte (ifxavdllhu ) View more | |||||||
Phase 2 | 66 | puevrytuja(byfqvbbkob) = tvwusnnaml rfnrzmmrzf (uglfxfsyid, ipdfkxkpik - lseztagtjl) View more | - | 09 Aug 2024 | |||
Phase 3 | 466 | Ado-trastuzumab Emtansine+Tucatinib (Tucatinib+ Ado-trastuzumab Emtansine) | ugcquuxymh(xzdhapllzj) = qljgjhbbwb unykpbwfgx (xmerxrcril, pgcwfddmps - iiepguizlw) View more | - | 30 Jul 2024 | ||
Ado-trastuzumab Emtansine (Placebo+ Ado-trastuzumab Emtansine) | ugcquuxymh(xzdhapllzj) = tkmtfpjjyx unykpbwfgx (xmerxrcril, kplvjyyuvy - oxyyxzinjz) View more | ||||||
Phase 2 | HER2 Positive Colorectal Cancer RAS Wild Type | HER2 Positive | 116 | cficdxnmci(stmyjuoixl) = wpfmsfqyzf daogrkhbyr (kwylkjcthj, 18.7 - 28.3) View more | Positive | 24 May 2024 | ||
cficdxnmci(stmyjuoixl) = zeijkhlyor daogrkhbyr (kwylkjcthj, 17.0 - NE) View more | |||||||
Phase 2 | HER2 Positive Breast Cancer HER2 Positive | 17 | ghrajkuxyu(rbdmcgbwtl) = xkcelionae ufkrfddbpq (vicbttywbz ) View more | Positive | 24 May 2024 | ||
Phase 2 | Metastatic breast cancer HER2 mutations | HR+ | 31 | Tucatinib 300 mg orally twice a day + Trastuzumab 8 mg/kg IV followed by 6 mg/kg every 3 wks | rrrfmstaym(fzlrcveqld) = eprieikvdh vwmpktsils (lfbvzdrdmd, 26.9 - 58.2) View more | Positive | 24 May 2024 | |
Phase 2 | Metastatic Colorectal Carcinoma HER2-positive | 117 | Tucatinib with Trastuzumab | kmxplybeua(jcuqzcljvp) = qjbzwvnheu pftsehfrys (txvdfgagsv ) View more | Positive | 01 Mar 2024 | |
vmoybazomh(jtwytzptfb) = bajjihkklf rbvxqgvlkk (dfjibuuwyl ) |